C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. - Test2 - elhamkhani - TriplyDB

C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

http://www.wikidata.org/entity/Q34167443

about

There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells.RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling RNA metabolism in neurodegenerative disease.A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD Cell-type specific differences in promoter activity of the ALS-linked C9orf72 mouse ortholog.Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function?Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier.Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis.C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence.Bromodomain inhibitors regulate the C9ORF72 locus in ALS Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease.Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing Emerging role of RNA•DNA hybrids in C9orf72-linked neurodegeneration.Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72.C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells.Quadruplex formation by both G-rich and C-rich DNA strands of the C9orf72 (GGGGCC)8•(GGCCCC)8 repeat: effect of CpG methylation.Solution structure of a DNA quadruplex containing ALS and FTD related GGGGCC repeat stabilized by 8-bromodeoxyguanosine substitution Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins.Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs Marked Differences in C9orf72 Methylation Status and Isoform Expression between C9/ALS Human Embryonic and Induced Pluripotent Stem Cells.C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins.Opening up the DNA methylome of dementia Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: a systematic neuropathological review.Conserved DNA methylation combined with differential frontal cortex and cerebellar expression distinguishes C9orf72-associated and sporadic ALS, and implicates SERPINA1 in disease.Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells.Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions.ALS and FTD: an epigenetic perspective.R Loops and Links to Human Disease.Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease.The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers.Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis.

P2860

Q26750577-78FB8BA7-4378-4AF0-93F8-3CC442A5EC8F Q26782984-66BDA5F6-CC88-4C81-A6F9-05FBF0F03924 Q26823908-A4135D96-1E25-4CC5-A24B-097D01BD48DD Q27687330-78FD1519-809A-47B6-84AA-4A1F76B93A08 Q28082520-4C7A8E95-64FB-4A2E-AC76-33DDE4055B6D Q29465544-C4AB0C3F-9A96-40F0-81E7-180CF9B1CAC7 Q33746283-4D51B375-B060-4FC5-B1C3-C17D71CC5483 Q33791480-6CDEFE08-DF98-4B14-A264-AAF3EE13B75C Q33915834-C1CBB00D-DA09-48EB-85F2-9B6592B01BD6 Q34157304-35813B0B-1DBE-4A80-A1B2-3470CAE7A25F Q34194063-381BCB6A-7B70-4ABE-9646-6134F6DA98F3 Q34810486-36C98B1B-B6FF-4E92-8C9A-7B68B4FA2F75 Q35204586-57AEE89A-D60E-4F2F-996B-2D47DDC3A640 Q35501931-05E11C15-9CF3-4059-A33B-F1D629859534 Q35537493-7C86C37B-72D0-47D0-99D3-D358140D74C5 Q35670978-C75FA71D-6736-4CE0-846C-133263090A02 Q35752114-707C2A84-75DA-4F87-8235-27AE39522C04 Q35985592-BD565CA6-E221-42B8-BC5F-B4476877BD8C Q36073675-3532A756-82BE-42DC-924A-00546F19E3CA Q36187621-F6AFF386-2621-4D11-8629-0EA253C9B2EE Q36304922-331405D6-991F-499F-ABBF-0000BC44E890 Q36600364-BDEC2312-3195-4573-9ABE-FC37B681EFDC Q36676565-B2AAE36D-1A02-400D-BC73-9E9A22E65296 Q36676726-F391EFF4-F625-40FD-AB72-099A85241CD4 Q36799853-DF5375D1-5F0B-4617-BA83-98961964F548 Q36880235-502F6183-E727-493A-ADDB-273B7053D7F6 Q37410193-FD0C8DE3-9558-4BA3-96E6-B190BF2EA00A Q37476206-648AB896-3122-44F5-8E78-869BB341FC84 Q37736146-6A1F0A55-5B7A-4116-82B0-1340790BD24B Q38587477-7A08CE21-D409-4CF6-BD61-38C22360E044 Q38624666-C94709B3-A1C2-4CA8-A49D-F9279744B6CC Q38741408-CF3D42BF-82C2-4EC2-A9AF-EB7AD5D48409 Q38789426-22E4B4C9-CD79-4EF6-8447-A1F830AFA812 Q38860456-56317761-5734-4905-8C7E-3BEBB6C43055 Q38947687-D51595C2-8111-40EF-87B3-29BF9F266F44 Q38952327-1CD7E7B8-E637-473B-B426-EDC03EAEAC91 Q39165154-9204B145-83FA-41C2-8D9C-B4C4031C039D Q40415783-7DE118B1-9FE2-4B38-9A28-8C823CDEF57C Q40535548-A4FCF6D5-21C8-47C3-A53D-D9DC304F53C1 Q40737530-5D75D7AD-18CE-4039-A104-FF693EFFEE9D

P2860

C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

http://www.wikidata.org/entity/Q34167443

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@ast

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@en

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@nl

type

label

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@ast

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@en

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@nl

prefLabel

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@ast

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@en

C9orf72 hypermethylation prote ...... sociated pathology in ALS/FTD.

@nl

P1433

Q34167443-269773B9-8063-4AFE-8097-94735DADE3B4

P1476

Q34167443-C9830B63-0A51-4DF5-9CB7-F4AACA369B79

P2093

Q34167443-0DA48CEF-E449-4242-9A16-35992E4DEF5E

Q34167443-1739C80C-27E8-463F-B6B6-FEBEDE72EAF5

Q34167443-5AEEF444-53D7-4928-9FE7-19CF7E7F48A4

Q34167443-97C1B480-7ECF-4BD6-A423-4BABF29AD0D8

Q34167443-98E80CAD-DF5A-44F6-A594-8FDB56222434

Q34167443-998C9F80-3CCE-4B80-B62B-F10C0AC376FC

Q34167443-CAC19179-3A3D-4587-B42C-5EA6D8D52257

Q34167443-CB5021C0-8741-4315-9FB5-7097C648AF6E

P2860

Q34167443-0040A45B-E287-45F9-B846-A8E3F37DA6F8

Q34167443-08D8E2B4-27CB-4E59-8418-08785AC45859

Q34167443-0ADB97D9-A2EE-4AE0-AA73-9A0C0C0EED0F

Q34167443-0C4BE50E-D9CC-4770-9852-EC9A9406F090

Q34167443-0D19FF54-D244-457D-B275-01ECE4117B7F

Q34167443-0E26A785-114D-4A94-9600-BC9343D3E7F5

Q34167443-1C6B3353-FA01-4575-A6FF-3C723AF6619F

Q34167443-1E5F7EFD-AF50-47FF-AD0E-A92AA2BD8690

Q34167443-21AE3A82-5C68-4BD3-AB8E-0A1EB50AEC2A

Q34167443-2332A431-A3C3-41F9-B049-7D18B5264744

P2888

Q34167443-41C73E62-CE05-42C6-B98E-8A1A33BF2F1E

P304

Q34167443-801FDFD5-FC19-4F8A-8219-72D07C43DAC3

P31

Q34167443-65070016-ADD8-47B6-8F01-71758C46EF9F

P356

Q34167443-E1F301FA-730A-4FA4-9E89-1BD224132090

P433

Q34167443-E4C0E13D-8451-4999-9DC2-BA1DD2332D1A

P478

Q34167443-E9725CD1-0002-46CC-8757-035C2082850A

P50

Q34167443-10B7A964-5A4E-4332-968E-736A6F9CB6EE

P577

Q34167443-71224D0B-155E-4617-BE20-4C0F91CC1F86

P5875

Q34167443-B5BA8A99-7DE0-4A89-8446-4F716DAEE212

P698

Q34167443-D58D6FEF-9E3F-4D76-9774-FD182A92BCD4

P921

Q34167443-2bba3279-92c6-448c-8c74-9ac15780deaf

Q34167443-78F899AB-C911-48DB-A083-B4246EF4E09C

P932

Q34167443-0526EA62-B8CE-49CD-9A08-2649E90848C8

P356

S00401-014-1286-Y

P1433

Acta Neuropathologica

P1476

C9orf72 hypermethylation prote ...... ssociated pathology in ALS/FTD

@en

P2093

Anna G McNally

http://www.w3.org/2001/XMLSchema#string

David J Irwin

http://www.w3.org/2001/XMLSchema#string

Donald Neal

http://www.w3.org/2001/XMLSchema#string

Edward B Lee

http://www.w3.org/2001/XMLSchema#string

Elaine Y Liu

http://www.w3.org/2001/XMLSchema#string

Eunran Suh

http://www.w3.org/2001/XMLSchema#string

Kathryn Wu

http://www.w3.org/2001/XMLSchema#string

Vivianna M Van Deerlin

http://www.w3.org/2001/XMLSchema#string

P2860

Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy

RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention

Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS

Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72

Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis

A decade of molecular studies of fragile X syndrome

P2888

s00401-014-1286-y

P304

525-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-014-1286-Y

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262147777

http://www.w3.org/2001/XMLSchema#string

P698

24806409

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

4161616

http://www.w3.org/2001/XMLSchema#string